Gilead and Galapagos Announce Positive Topline Results of Phase 2b/3 Trial of Filgotinib in Moderately to Severely Active Ulcerative Colitis

FOSTER CITY, Calif. & MECHELEN, Belgium--(BUSINESS WIRE)--May 20, 2020-- Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext& Nasdaq: GLPG) today announced positive topline results from SELECTION, a...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials